Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children

Steven Paul Nisticò, Rosita Saraceno, Elisabetta Capriotti, Catia De Felice, Sergio Chimenti

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To demonstrate the efficacy of light produced by a 308 nm xenon-chloride monochromatic excimer light (MEL) in the treatment of localized lesions of atopic dermatitis (AD) in adults and in children. Background Data: The 308-nm excimer light has been reported to be safe and effective in the treatment of chronic skin diseases, although the range of potential applications has not been fully explored. Methods: Twelve adults and six children affected by localized lesions of AD were enrolled in this pilot study and treated with a weekly session of MEL. A range of 6-12 sessions was performed with an increasing dosage according to the patient's phototype and response. Follow-up was for 16 wk. Results: All patients completed the protocol. At the end of treatment complete remission was observed in 12/18 patients (66.7%), a partial remission in 3/18 (16.7%) and no remission in 3/18 (16.7%). A mean total dose of 21.89 minimal erythemal dose (MED) was performed. Forty-four percent of patients maintained the results achieved at a 16-week follow-up. Treatment was well tolerated overall. Conclusions: MEL can be considered as a valid and safe therapeutic option for the treatment of localized AD in adults and children.

Original languageEnglish
Pages (from-to)14-18
Number of pages5
JournalPhotomedicine and Laser Surgery
Volume26
Issue number1
DOIs
Publication statusPublished - Feb 1 2008

Fingerprint

Atopic Dermatitis
Light
Therapeutics
Xenon
Skin
Skin Diseases
Chronic Disease

ASJC Scopus subject areas

  • Biomedical Engineering
  • Surgery
  • Dermatology
  • Oral Surgery

Cite this

Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. / Nisticò, Steven Paul; Saraceno, Rosita; Capriotti, Elisabetta; Felice, Catia De; Chimenti, Sergio.

In: Photomedicine and Laser Surgery, Vol. 26, No. 1, 01.02.2008, p. 14-18.

Research output: Contribution to journalArticle

Nisticò, Steven Paul ; Saraceno, Rosita ; Capriotti, Elisabetta ; Felice, Catia De ; Chimenti, Sergio. / Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children. In: Photomedicine and Laser Surgery. 2008 ; Vol. 26, No. 1. pp. 14-18.
@article{09504b27a8bb437bb007e316972f76b0,
title = "Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children",
abstract = "Objective: To demonstrate the efficacy of light produced by a 308 nm xenon-chloride monochromatic excimer light (MEL) in the treatment of localized lesions of atopic dermatitis (AD) in adults and in children. Background Data: The 308-nm excimer light has been reported to be safe and effective in the treatment of chronic skin diseases, although the range of potential applications has not been fully explored. Methods: Twelve adults and six children affected by localized lesions of AD were enrolled in this pilot study and treated with a weekly session of MEL. A range of 6-12 sessions was performed with an increasing dosage according to the patient's phototype and response. Follow-up was for 16 wk. Results: All patients completed the protocol. At the end of treatment complete remission was observed in 12/18 patients (66.7{\%}), a partial remission in 3/18 (16.7{\%}) and no remission in 3/18 (16.7{\%}). A mean total dose of 21.89 minimal erythemal dose (MED) was performed. Forty-four percent of patients maintained the results achieved at a 16-week follow-up. Treatment was well tolerated overall. Conclusions: MEL can be considered as a valid and safe therapeutic option for the treatment of localized AD in adults and children.",
author = "Nistic{\`o}, {Steven Paul} and Rosita Saraceno and Elisabetta Capriotti and Felice, {Catia De} and Sergio Chimenti",
year = "2008",
month = "2",
day = "1",
doi = "10.1089/pho.2007.2116",
language = "English",
volume = "26",
pages = "14--18",
journal = "Photomedicine and Laser Surgery",
issn = "1549-5418",
publisher = "Mary Ann Liebert Inc.",
number = "1",

}

TY - JOUR

T1 - Efficacy of monochromatic excimer light (308 nm) in the treatment of atopic dermatitis in adults and children

AU - Nisticò, Steven Paul

AU - Saraceno, Rosita

AU - Capriotti, Elisabetta

AU - Felice, Catia De

AU - Chimenti, Sergio

PY - 2008/2/1

Y1 - 2008/2/1

N2 - Objective: To demonstrate the efficacy of light produced by a 308 nm xenon-chloride monochromatic excimer light (MEL) in the treatment of localized lesions of atopic dermatitis (AD) in adults and in children. Background Data: The 308-nm excimer light has been reported to be safe and effective in the treatment of chronic skin diseases, although the range of potential applications has not been fully explored. Methods: Twelve adults and six children affected by localized lesions of AD were enrolled in this pilot study and treated with a weekly session of MEL. A range of 6-12 sessions was performed with an increasing dosage according to the patient's phototype and response. Follow-up was for 16 wk. Results: All patients completed the protocol. At the end of treatment complete remission was observed in 12/18 patients (66.7%), a partial remission in 3/18 (16.7%) and no remission in 3/18 (16.7%). A mean total dose of 21.89 minimal erythemal dose (MED) was performed. Forty-four percent of patients maintained the results achieved at a 16-week follow-up. Treatment was well tolerated overall. Conclusions: MEL can be considered as a valid and safe therapeutic option for the treatment of localized AD in adults and children.

AB - Objective: To demonstrate the efficacy of light produced by a 308 nm xenon-chloride monochromatic excimer light (MEL) in the treatment of localized lesions of atopic dermatitis (AD) in adults and in children. Background Data: The 308-nm excimer light has been reported to be safe and effective in the treatment of chronic skin diseases, although the range of potential applications has not been fully explored. Methods: Twelve adults and six children affected by localized lesions of AD were enrolled in this pilot study and treated with a weekly session of MEL. A range of 6-12 sessions was performed with an increasing dosage according to the patient's phototype and response. Follow-up was for 16 wk. Results: All patients completed the protocol. At the end of treatment complete remission was observed in 12/18 patients (66.7%), a partial remission in 3/18 (16.7%) and no remission in 3/18 (16.7%). A mean total dose of 21.89 minimal erythemal dose (MED) was performed. Forty-four percent of patients maintained the results achieved at a 16-week follow-up. Treatment was well tolerated overall. Conclusions: MEL can be considered as a valid and safe therapeutic option for the treatment of localized AD in adults and children.

UR - http://www.scopus.com/inward/record.url?scp=38849206396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849206396&partnerID=8YFLogxK

U2 - 10.1089/pho.2007.2116

DO - 10.1089/pho.2007.2116

M3 - Article

C2 - 18248156

AN - SCOPUS:38849206396

VL - 26

SP - 14

EP - 18

JO - Photomedicine and Laser Surgery

JF - Photomedicine and Laser Surgery

SN - 1549-5418

IS - 1

ER -